Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries
Open accessThe DOI matches its Crossref record; 47 of the 52 references it cites were found in a registry or an index; 6 of the 17 sources its claims cite were checked for support.
Abstract
Systematic review of 38 studies on whether procurement and supply chain changes achieve cost savings and improve availability of health products in LMICs.
Overview
CoChat Summary
TL;DR
This systematic review found that changes to supply chains and procurement processes in low- and middle-income countries often reduce costs and sometimes improve availability of pharmaceuticals, vaccines, and other health products. Centralised procurement/tendering showed cost savings across many contexts, while supply chain management programmes often reduced stock-outs and increased availability.
Key findings
- The review screened 1,264 articles and included 38 studies: 25 on cost implications and 15 on availability, with 2 studies contributing to both groups.
- Of the 25 references analysing cost implications, 23 found a reduction in costs to the health system; 12 of these focused on centralised procurement or tendering.
- Centralised procurement produced reported savings such as 5.2–17% cost savings on drugs in Jordan, US$52.1 million–US$121.8 million in savings in Mexico over the first 4 years, and a 79% reduction in annual ARV cost per person in Brazil over 6 years (1997 to 2003).
- Of the 15 references analysing availability, 13 found improvements; supply chain management programmes were linked to reduced stock-outs and increased availability, including increases from 40% to 70% before implementation to >90% after implementation in Delhi, India.
Methods
- Systematic review conducted using PRISMA guidelines.
- Searched PubMed, Embase, CINAHL, and the Health Economic Evaluation Database; included original peer-reviewed studies in English reporting actual interventions in LMICs.
- Included studies had to evaluate an intervention changing procurement or supply chains and report cost changes or product availability; the review used comparative outcome measures and excluded baseline costing studies and non-intervention reports.
Limitations
- The paper states that studies used many different metrics, making it hard to compare or synthesise findings across studies.
- It states that many studies did not use experimental designs, and there is likely publication bias toward positive results; very few studies reported negative outcomes.
- Evident from the text: the review’s conclusions are constrained by context-specific interventions, so effects may not generalise well across settings; the paper explicitly says one cannot predict the impact of a specific programme in another context.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 8 Not checked · 16 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“and a 48.4% reduction in cost of drugs needed to treat gastroenteritis (statistical significance not reported).”
§ Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries > Results > Comprehensive drug system policies
What the sources say
- Supportedcites [14] source
The “Reduced charges for patients” section reports 48.4% lower drug costs for inpatients admitted with gastroenteritis after local implementation of the scheme in the three study provinces. It does not report statistical significance for that figure. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“One reference about a centralised procurement process for antimalarials in Kenya found that a delay in the process, and the awarding of the tender to a relatively new, unknown company, resulted in a nationwide increase in stock outs.12”
§ Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries > Results > Study selection
What the sources say
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
In 'The Kenya case' (page unavailable), the paper says Kenya awarded the antimalarial tender to a relatively unknown company and that delays and the company's failure to supply sufficient medicine exacerbated widespread stock-outs. It does not describe the company as relatively new or establish a nationwide increase in stock-outs; it says the stock-outs were already widespread and were prolonged. (LLM, conf=0.84)
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“An evaluation of this scheme in three provinces found that it resulted in a 17.5% reduction in cost of drugs needed to treat pneumonia or bronchitis (p<0.05)”
§ Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries > Results > Comprehensive drug system policies
What the sources say
- Supportedcites [14] source
The ‘Reduced charges for patients’ section reports that drug expenses for inpatients with pneumonia or bronchitis were 17.5% lower after implementation of the scheme. Table 3 identifies this as the combined result for adult inpatients in the three provinces and marks it as statistically significant (P < 0.05). (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“one programme in Senegal used an informed Push Model, in which projected demand dictates quantities of drug orders, to reduce stock outs for contraceptives,32”
§ Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries > Results > Supply chain/cold chain management
What the sources say
- Partly supportedcites [32] sourceExperimental — accuracy not yet measured
The Conclusion says the informed push model was an effective solution to contraceptive stockouts in Senegal. The Strategy for Change says logisticians restocked facilities to maintain about two months of estimated supply needs, but it also says the model eliminated facility orders. Thus the stockout claim is supported, while the citing sentence’s description of projected demand dictating drug orders is not. (LLM, conf=0.84)
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“and increased availability of ACTs in various countries in Sub-Saharan Africa.36 37”
§ Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries > Results > Other types of programmes
What the sources say
- Not checked — no full text of the sourcecites [36] source
- Partly supportedcites [37] sourceExperimental — accuracy not yet measured
The Results (Stocking; page not provided) show that ACT availability increased in shops in two intervention districts in Tanzania. The Introduction identifies this as a pilot of the AMFm model, not evidence that the AMFm increased availability in various Sub-Saharan African countries. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
21 more claims
Create a free account to see all 31 claims and to verify the 2 references still open.
- It may state two separate claims as one. 5
- Probably not a substantial claim. 1
Citations
Cites
Getting Health Reform Right: A Guide to Improving Performance and Equity
Roberts, M., Hsiao, W., Berman, P., & Reich, M. (2008) · doi:10.1093/acprof:oso/9780195371505.001.0001 · Cited by 444
Bossert, T. J. (2002) · Health Policy and Planning · doi:10.1093/heapol/17.1.14 · Cited by 396 · cited 1×
“Handling editor Seye Abimbola.”
Countering the Problem of Falsified and Substandard Drugs
Committee on Understanding the Global Public Health Implications of Substandard, F., Board on Global Health, & Institute of Medicine (2013) · National Academies Press eBooks · doi:10.17226/18272 · Cited by 209
Tougher, S., Ye, Y., Amuasi, J. H., Kourgueni, I. A., Thomson, R., Goodman, C., Mann, A. G., Ren, R., Willey, B. A., Adegoke, C. A., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61732-2 · Cited by 173
Assessing Public Expenditure on Health from a Fiscal Space Perspective
Tandon, A., & Cashin, C. (2010) · World Bank, Washington, DC eBooks · doi:10.1596/13613 · Cited by 158
Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement
Danzon, P. M., Mulcahy, A. W., & Towse, A. (2013) · Health Economics · doi:10.1002/hec.3013 · Cited by 154
Essential medicines are more available than other medicines around the globe
Bazargani, Y. T., Ewen, M., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087576 · Cited by 126
DeRoeck, D., Bawazir, S. A., Carrasco, P., Kaddar, M., Brooks, A., Fitzsimmons, J., & Andrus, J. (2006) · The International Journal of Health Planning and Management · doi:10.1002/hpm.822 · Cited by 106 · cited 1×
“Of these three references, one programme in Nigeria aimed at strengthening laboratory services in hospitals reduced the costs of conducting laboratory tests by increasing the total volume of tests and then purchasing reagents in bulk at reduced”
BackgroundSabot, O. J., Mwita, A., Cohen, J. M., Ipuge, Y., Gordon, M., Bishop, D., Odhiambo, M., Ward, L., & Goodman, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006857 · Cited by 105
‘DOI MOI ’ AND HEALTH: THE EFFECT OF ECONOMIC REFORMS ON THE HEALTH SYSTEM IN VIETNAM
Witter, S. (1996) · The International Journal of Health Planning and Management · doi:10.1002/(sici)1099-1751(199604)11:2<135::aid-hpm422>3.0.co;2-1 · Cited by 96 · cited 1×
“These references included joint procurement across multiple countries, including the Gulf Cooperation Council (GCC) of Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and UAE,(16) 17 the PAHO Expanded Program on Immunisation (EPI) which included many Latin American countries(16) and the Eastern Caribbean Drug Service (ECDS…”
Background
Research works printed but not linked: 3
- 10.1002/(SICI)1099-1751(199706)12:1+<S29::AID-HPM465>3.3.CO;2-L · doi:10.1002/(sici)1099-1751(199706)12:1+<s29::aid-hpm465>3.3.co;2-l
- Embrey M . Chapter 13: Revolving drug funds and user fees. In: Management Sciences for Health, eds. MDS-3: managing access to medicines and health technologies. Arlington (VA): Management Sciences for Health, 2012.
- Barraclough A , Clark M . Chapter 18: managing procurement. In: Management Sciences for Health, eds. MSD-3 managing access to medicines and health technologies. Arlington (VA): Management Sciences for Health, 2012.
Cited by
(2009) · OECD health policy studies · doi:10.1787/2074319x · Cited by 221
Kohler, J. C., & Dimancesco, D. (2020) · Global Health Action · doi:10.1080/16549716.2019.1694745 · Cited by 128
“The health system as a whole may become less effective and equitable [14].”
BackgroundVledder, M., Friedman, J. A., Sjoblom, M. C., Brown, T., & Yadav, P. (2019) · Health Systems & Reform · doi:10.1080/23288604.2019.1596050 · Cited by 113
“Despite the increasing awareness about the importance of efficient logistics systems for attainment of health outcomes, systematic analysis of essential drugs distribution system and their impact on stockout rates at the point of service delivery and priority health outcomes remains limited.(5) Few studies have invest…”
BackgroundChen, L., Yang, Y., Luo, M. Y., Hu, B., Yin, S., & Mao, Z. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17249415 · Cited by 94
“Globally, centralized drug procurement successfully saves drug costs [10,11].”
BackgroundA systematic review of pooled procurement of medicines and vaccines: identifying elements of success
Parmaksiz, K., Pisani, E., Bal, R. A., & Kok, M. O. (2022) · Globalization and Health · doi:10.1186/s12992-022-00847-z · Cited by 101
“Similar to Seidman and Atun’s [19] observations, we noticed that the majority of the studies included provided examples of pooled procurement mechanisms that have been set up successfully.”
BackgroundResultInfluential
Metadata
- Authors
- Seidman, G., & Atun, R.
- Affiliations
- Harvard University (US)
- Corresponding author
- Seidman, Gabriel
- Venue
- BMJ Global Health
- Publisher
- BMJ
- Published
- 2017-04
- Volume
- 2
- Issue
- 2
- Pages
- e000243
- ISSN
- 2059-7908 (ISSN-L)
- PMC
- PMC5435270
- OpenAlex
- W2607163485
- Cited by
- 133
- References
- 52
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 26 · 2023: 15 · 2022: 15 · 2021: 19 · 2020: 9 · 2019: 8 · 2018: 3 · 2017: 2
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Global Health (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- Bill and Melinda Gates Foundation
- Rockefeller Foundation
- Harvard T.H. Chan School of Public Health
- Bloomberg Philanthropies
- GE Foundation
- Harvard Kennedy School
- Harvard Graduate School of Education
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
- Social Sciences › Decision Sciences › Management Science and Operations Research › Supply Chain and Inventory Management
- Keywords
- pharmaceutical supply chain, tendering, drug stock-outs, drug availability, cost reduction, health system efficiency, vaccines, low- and middle-income countries, health system performance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries. https://app.cochat.ai/papers/10.1136/bmjgh-2016-000243
- The paper
- Seidman, G., & Atun, R. (2017). Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries. BMJ Global Health. https://doi.org/10.1136/bmjgh-2016-000243
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
